Repatha Sees 37% Sales Growth as Biotech Industry Continues to Evolve
Pharmaceutical company Amgen's Repatha drug has seen significant growth in sales, increasing by 37%.
This news comes as a positive development for investors and fans of the biotech industry.
The exact reasons behind this surge in demand are not specified in the report from Pluang, but it is likely due to various factors such as increased marketing efforts or advancements in medical research.